NCT06117046

The Cardio-protective Effect of Cardiomyopeptidin on Myocardial Injury in ICU Patients With Non-organic Heart Disease: a Prospective, Single-blind, Randomized Controlled Pilot Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 234 (actual)
• Sponsor: Nanfang Hospital, Southern Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study was a single-center, randomized controlled pilot study. To explore the cardioprotective effect of cardiopeptidin on non-heart disease patients with severe cardiac injury by comparing whether cardiopeptidin was used.

Conditions

• Myocardial Injury
• ICU

Interventions

Type	Name	Description
DRUG	Cardiopeptidin	Cardiopeptidin was administered intravenously once a day with cardiopeptidin for 3 days.The dosing regimen follows the recommended dosage of 1 mg/kg/day as outlined in the product manual, with doses calculated based on the ideal body weight.
DRUG	50 ml of normal saline intravenous infusion	50 ml of normal saline intravenous infusion

Timeline

• Start date: 2023-02-27
• Primary completion: 2023-11-25
• Completion: 2023-11-25
• First posted: 2023-11-03
• Last updated: 2025-02-13

Locations

1 site across 1 country: China